Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR1F | P30939 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3831731 | 0.96 | NPC1 (0.46) | RAB9ANPC1SMN1; SMN2CYP1A2HPGD | |
| SCHEMBL3833813 | 0.93 | HTR1F (0.47) | RAB9ANPC1SMN1; SMN2CYP1A2HPGD | |
| SCHEMBL3832660 | 0.93 | MAP3K5 (0.39) | RAB9ANPC1SMN1; SMN2CYP1A2HPGD | |
| SCHEMBL3827682 | 0.87 | CCNE1 (0.42) | MAPTCCNE1CDK2TP53ALDH1A1 | |
| SCHEMBL3826203 | 0.85 | MAPK14 (0.43) | RAB9ANPC1MAP3K5HTR1AHTR1F | |
| SCHEMBL4402104 | 0.85 | RAB9A (0.45) | RAB9ANPC1SMN1; SMN2MAP3K5MAPT | |
| SCHEMBL3815728 | 0.84 | ADRA2A (0.45) | RAB9ANPC1SMN1; SMN2CYP1A2HPGD | |
| SCHEMBL3833014 | 0.84 | RAB9A (0.41) | RAB9ANPC1SMN1; SMN2HPGDMAP3K5 | |
| SCHEMBL4391744 | 0.84 | RAB9A (0.42) | RAB9ANPC1SMN1; SMN2MAP3K5MAPT | |
| SCHEMBL3833164 | 0.84 | RAB9A (0.42) | RAB9ANPC1SMN1; SMN2MAP3K5ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306100-A1 | METHODS OF TREATING SCHIZOPHRENIA | LEXICON PHARMACEUTICALS, INC. | 2009-12-10 | — | — | US | disclosed |
| EP-2089018-A2 | METHODS OF TREATING COGNITIVE IMPAIRMENT AND DEMENTIA | Lexicon Pharmaceuticals, Inc. (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20080153811-A1 | methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. | LEXICON PHARMACEUTICALS, INC. | 2008-06-26 | — | — | US | disclosed |
| WO-2008067121-A2 | METHODS OF TREATING COGNITIVE IMPAIRMENT AND DEMENTIA | LEXICON PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20070049608-A1 | Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
| WO-2006124897-A2 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITION | LEXICON GENETICS INCORPORATED (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060258691-A1 | Methods and compositions for improving cognition | LEXICON PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153811-A1 | methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. | CHAT, PSEN2, PSEN1 | RAB9A 1214/4885NPC1 76/4885SMN1; SMN2 614/4885 |
| US-20090306100-A1 | METHODS OF TREATING SCHIZOPHRENIA | CHAT, GAP43, GRIN2A | RAB9A 1054/4885NPC1 308/4885SMN1; SMN2 1292/4885 |
| US-20060258691-A1 | Methods and compositions for improving cognition | PSEN1, PSEN2, APP | RAB9A 808/4885NPC1 256/4885SMN1; SMN2 31/4885 |
| US-20070049608-A1 | Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use | DPYD, TYMP, PNKP | RAB9A 2588/4885NPC1 3748/4885SMN1; SMN2 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.